Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Pancreatic Neoplasms 2Colonic Neoplasms 2Thyroid Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 29Carboplatin 10Surveys and Questionnaires 9Paclitaxel 9Trastuzumab 8Nivolumab 8Cisplatin 8Taxes 7Gemcitabine 7Bevacizumab 6Specimen Handling 5Oxaliplatin 5Irinotecan 5Fluorouracil 5Cetuximab 5Biopsy 5spartalizumab 4Leucovorin 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4tisotumab vedotin 3fludarabine 3durvalumab 3atezolizumab 3aldesleukin 3X-Rays 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Interviews as Topic 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Camptothecin × Gastrointestinal × Clear all
NCT00333502 2020-05-28

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Lumos Pharma

Phase 1/2 Completed
62 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡